Canaccord Genuity Maintains Buy on Guardant Health, Lowers Price Target to $30
Guardant Health -2.35%
Guardant Health GH | 20.35 | -2.35% |
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:
GH) with a Buy and lowers the price target from $45 to $30.